Cargando…
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Activation of the PI3K-mTOR pathway is central to breast cancer pathogenesis including resistance to many targeted therapies. The mTOR kinase forms two distinct complexes, mTORC1 and mTORC2, and understanding which is required for the survival of malignant cells has been limited by tools to selectiv...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328828/ https://www.ncbi.nlm.nih.gov/pubmed/37264081 http://dx.doi.org/10.1038/s41388-023-02737-z |